chain reaction (RT-PCR) based methods for detecting mRNA of tumour cell-derived products (Mattano et al, 1992; Craig et al, 1994; Vannucchi et al, 1998) .
In the present study, using nested RT-PCR for detecting alphafetoprotein (AFP) mRNA, we obtained evidence of tumour cell contamination in PBSC fractions from advanced GCT patients. Furthermore, we also found that the amount of AFP mRNA decreased with repeated cycles of combined chemotherapy.
MATERIALS AND METHODS

Patient samples
We evaluated, retrospectively, PBSC frozen samples from 5 patients with advanced testicular GCT and elevated serum AFP (range 26-44 years old, mean age 32). The clinical stages and pathological diagnoses are shown in Table 1 . All patients had visceral involvement and/or lymph node (LN) metastasis. They had undergone orchiectomy, and received 3 cycles of a conventional chemotherapy regimen, EP or BEP (VP-16 100 mg m -2 , cisplatin 20 mg m -2 and bleomycin 30 U) ( Table 2) . Mobilization of haematopoietic stem cells in the peripheral blood was performed by daily injections of recombinant G-CSF (75 µg m -2 filgrastim/day -1 , s.c. or 100 µg m -2 lenograstim day -1 , s.c.) until the number of leukocytes reached 10 000 µl -1 . Mononuclear cells (MNC) were collected using an AS104 separator, and 7.2 litres of blood was processed per leukopheresis. Each MNC fraction was centrifuged, resuspended in albumin, DMSO and starch mixture, and stored at -80˚C until use. Two or 3 consecutive leukophereses per cycle were performed to harvest a total of more than 2 × 10 6 CD34 + cells per kg of body weight. ) and carboplatin (320 mg m -2 ) on days -6 to -2 (patient 5 died before HDC due to carcinomatous meningitis). At the time of transplant, one or two subsets of harvested cells (total number of CD34+ cells was 2 × 10 6 per kg of body weight) were reinfused to each patient (Table 3) .
Sequential detection of alphafetoprotein-bearing cells in
RNA isolation from PBSC harvests
RNA was isolated from 1 ml of processed fraction containing approximately 1 × 10 7 MNC, which was aliquoted at PBSC collection. Cells were thawed in a 37˚C water bath, and wahsed once in sterile phosphate-buffered saline (PBS). Cells were processed using the SV total RNA isolation system (Promega, Madison, WI) according to the manufacturer's instructions, and resuspended in 100 µl of diethyl pyrocarbonate-treated (DEPC) water.
Cell line
The Hep 3B human hepatocellular carcinoma cell line, which secretes AFP, was used as a control (Knowles et al, 1980; Jiang et al, 1997) . The cell line was kindly provided by Dr Toshio Kudo (Institute of Development, Aging and Cancer, Tohoku University, Sendai, Japan). Cells were cultured in RPMI-1640 medium supplemented with 10% fetal calf serum in 5% CO 2 / 95% air at 37˚C. To check the sensitivity of the assay, 1 × 10 7 peripheral MNC from a healthy volunteer were mixed with serial dilutions of Hep 3B cells (1 × 10 3 -10 0 ).
Nested RT-PCR amplification of AFP mRNA
cDNA synthesis and RT-PCR were performed as described previously (Bilim et al, 1998) . Briefly, aliquots of 8.2 µl RNA were used and synthesis of cDNA was performed in a 20-µl reaction using a first-strand cDNA synthesis kit (Boehringer Mannheim, Indianapolis, IN). The mixture was incubated at 25˚C for 10 Patients described in Table 1 . EP: VP-16, cisplatin; BEP: bleomycin, VP-16, cisplatin; CR = complete remission; PR = partial remission; NC = no change; Harvest 1-3: harvest during the first, second and third cycle of chemotherapy, respectively; X: not measured; ND: PBSC apheresis during that cycle was not performed. minutes and then at 42˚C for 60 minutes. The reaction was stopped by enzyme inactivation at 95˚C for 5 minutes. Before analysis, amplification of the constitutively expressed β-actin gene was performed to ensure appropriate first-strand cDNA synthesis. The nested PCR was conducted by adding 1 µl of cDNA to 50 µl of reaction buffer (10 mM Tris-HCl, pH 8.3, 50 mM KCl, 1.5 mM MgCl 2 and 200 mg ml -1 gelatin), with 200 µM of each dNTP, 400 nM of each outer primer and 2.5 units of AmpliTaq Gold™ (Perkin Elmer, Branchburg, NJ). 40 cycles of 1 min denaturation at 94˚C, 1 min annealing at 52˚C and 1 min extension step at 72˚C were performed in a thermal cycler (Perkin Elmer). A sample of 1 µl of the first amplification product was subjected to the nested amplification using inner primer pairs with the same reagents and protocol. The amplified products were analysed by electrophoresis on a 3% agarose gel. Two sets of primers specific for the AFP cDNA sequence were designed (Morinaga et al, 1983) . The outer pair of primers were sense: 5′-ACTGAATCCA-GAACACTGCATAG-3′ (nucleotides 90-112, in exon 1) and antisense: 5′-TGCAGTCAATGCATCTTTCACCA-3′ (nucleotides 263-241, in exon 3). The inner pair of primers were sense: 5'-TGGAATAGCTTCCATATTGGATTC-3′ (nucleotides 122-145, over exon 1 and exon 2, antisense: 5′-AAGTGGCTTCTTGAA-CAAACTGG-3′ (nucleotides 222-200, in exon 3) (Komeda et al, 1995) . Since the inner sense primer was designed to bridge the intron, the competition of contaminating genomic DNA could be eliminated. The identity of the amplified products was confirmed by direct sequencing (data not shown). Each PCR reaction was performed in triplicate to confirm the accuracy of the findings.
RESULTS
Specificity and sensitivity of the nested RT-PCR assay for AFP
Using cDNA from Hep 3B cells, which secrete AFP, specific bands (101 bp) were detected (Figure 1 ). Peripheral MNC obtained from healthy volunteers (approximately 1 × 10 7 cells) were used as the negative control. We also examined PBSC fractions from 3 other patients whose primary testicular tumours did not contain AFP-producing cells (two of them were diagnosed as seminoma and one was choriocarcinoma). No detectable mRNA was found in the harvests obtained after any cycle of conventional chemotherapy (data not shown).
The sensitivity of the nested PCR was determined by simulating a contamination model with a different number of Hep 3B cells into MNC obtained from a healthy volunteer. As few as 10 Hep 3B cells were detected among 1 × 10 7 MNC (Figure 1 ).
Nested PCR analysis of PBSC fractions from AFP producing GCT patients
The patient characteristics are summarized in Table 1 . In the primary tumours, the presence of embryonal carcinoma (EC) and/or yolk sac tumour (YST), either of which may produce AFP, was confirmed histopathologically. In all patients, AFP mRNA was detected in PBSC fractions harvested after the first and second cycle of conventional chemotherapy. In contrast, in 3 of 4 samples obtained after the third cycle, AFP mRNA was not detected (Figure 2 , patients 3-5).
Comparison between AFP mRNA detection and serum AFP levels
PBSC apheresis during elevated serum AFP (over 10 ng ml -1 ) resulted in detection of AFP mRNA-bearing cells in PBSC fractions in all cases except one. Patient 4 was the only exception. His serum AFP remained high even after HDC, but AFP mRNA in PBSC fraction after the third cycle of induction chemotherapy was not detected. On CT he had cystic residual tumours. Surgical resection of the residual tumours revealed a cystic mass without viable cancer cells, which contained fluid with a high concentration of AFP, leading to elevated serum AFP. As for patient 3, serum AFP decreased to within the normal range by the time of the second cycle of chemotherapy, but AFP mRNA was detected in the PBSC fraction obtained after that cycle. , 10 1 and 10 0 Hep 3B cells. RNA was isolated from each mixture, and cDNA was prepared using random primers. Nested PCR using AFP primers was performed. The 176 and 101 base pair fragments were amplified from outer and inner primer pairs, respectively (upper). In all samples, the presence of adequately amplified mRNA had been assessed by RT-PCR of the β-actin gene (lower). remission by administration of 3 cycles of chemotherapy. However, he died due to carcinomatous meningitis 5 months after the end of chemotherapy without evidence of involvement of other organs. The remaining 4 patients underwent HDC with PBSCT following induction chemotherapy because of partial remission or no clinical response (details of PBSC infusion are shown in Table 3 ). Patient 1 died during the myelosuppression phase (3 days after PBSCT) due to infection. Two patients (patients 3-4) received resection of residual tumours after HDC. Those tumours did not contain cancer cells histopathologically. Those patients remained alive without disease (mean follow up 36 months). Retrospectively, however, patient 2 was transplanted with AFP mRNA positive fraction (Table 3) although he was alive without evidence of recurrence (more than 5 years).
DISCUSSION
Although RT-PCR can detect tumour cells with higher sensitivity than the histological or immunocytochemical methods which have been commonly used (Mapara et al, 1997; Vannucchi et al, 1998) , low specificity remains a problem (Ghossein et al, 1999) . In the present study, to exclude false positive results, MNC from healthy volunteers and PBSC fractions from AFP non-producing GCT patients were examined by nested RT-PCR, but no AFP signals were detected. Moreover, direct sequence of the amplified products of a positive control revealed accurate AFP cDNA. The sensitivity of this assay was a single tumour cell per 1 × 10 6 MNC. We were able to detect circulating AFP-bearing cells even in the fraction where the serum AFP level decreased to within the normal range during chemotherapy. Although the sensitivity of AFP RT-PCR could be further improved (Ghossein et al, 1999) , at the present state, it might be a useful modality to predict metastatic disease in germ cell tumours. Besides, detection of AFP mRNAbearing cells in PBSC fraction may reveal the presence of refractory residual disease after induction chemotherapy. In all samples harvested after the first and second cycle, AFP mRNA was detected. It was shown that mRNA of β human chorionic gonadotropin (β-HCG), another germ cell tumour marker, was also detected in the PBSC fractions of GCT patients (Fan et al, 1998) . Moreover, in the 3 of 4 samples after the third cycle, AFP mRNA was not detected. Our results are in agreement with the clearance of circulating tumour cells in blood samples during chemotherapy in neuroblastoma patients (Moss et al, 1990) . These findings imply a possibility of reducing minimal residual tumour cell load (i.e. in vivo purging) by multiple cycles of conventional chemotherapy. Thus, the use of PBSCs after 3 cycles of conventional chemotherapy might reduce the possibility of recurrence due to tumour cell contamination in the fraction, although relapse may take place due to the tumour cells remaining inside the body even after chemotherapy. This is supported by the findings of Vredenburgh et al (1997) , who reported that the higher the number of tumour cells identified in the bone marrow harvest, the shorter the disease-free and overall survival.
A variety of techniques have been proposed to purge tumour cells ex vivo (Gribben et al, 1991; Vogel et al, 1996; Spyridonidis et al, 1998) . Although prospective randomized trials remain to be investigated to determine whether a positive selection of haematopoietic progenitor cells and/or depletion of tumour cells contaminating PBSC fraction affects clinical outcome, the combination of in vivo and ex vivo purging might become an attractive strategy to improve patient survival.
However, one patient who received PBSCT with AFP mRNA positive cells remained free from recurrence after more than 5 years follow-up. Cooper et al (1998) demonstrated that tumour cells contaminated in PBSC fractions from advanced breast cancer patients were capable of clonogenic growth in vitro, but the authors were unable to find a significant correlation of occult tumour reinfusion with time to progression or overall survival. Tumour cells contaminated in PBSC fractions may not have the capacity to grow in vivo, possibly due to killing by host immune cells (Kennedy et al, 1994) . Thus, the presence or absence of AFP mRNA-bearing cells may not necessarily determine recurrence of a tumour after HDC and PBSCT.
In summary, we showed the presence of AFP mRNA-bearing cells in PBSC fractions from GCT patients. The nested RT-PCR method may be useful for detecting circulating tumour cells with high sensitivity. Furthermore, in the administration of HDC with PBSCT, it may assist the determination of the best timing of harvest. Although larger patient groups and different purging trials are required, the present findings suggest that harvesting PBSC after multiple cycles of induction chemotherapy in advanced GCT patients might be recommended in terms of a reduced risk of tumour cell contamination.
